Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dactolisib - resTORbio

Drug Profile

Dactolisib - resTORbio

Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; resTORbio
  • Class 3-ring heterocyclic compounds; Acetonitriles; Antineoplastics; Antivirals; Benzenesulfonates; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory tract infections
  • Phase II Influenza virus infections
  • Phase I/II Parkinson's disease
  • Phase I Heart failure; Urinary tract infections
  • Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 02 Oct 2019 Efficcay, safety and pharmacodynamics data from a phase IIb trial in Respiratory tract infections released by resTORbio
  • 07 Jul 2019 Phase-III clinical trials in Respiratory tract infections (In the elderly, Prevention) in Canada, USA (PO) (NCT04139915)
  • 07 Jul 2019 Phase-III clinical trials in Respiratory tract infections (In the elderly, Prevention) in United Kingdom and Germany (PO) (EudraCT2019-002014-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top